Market Intelligence, Clinical Progress, and High-Purity Reagents for Mitochondrial Iron Homeostasis and Ferroptosis-Targeted Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FTMT drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FTMT Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW. E. coli or Mammalian expressed. |
View FTMT Products |
| Gene Delivery | FTMT Promise-ORF / Lentivirus Full-length ORF for stable cell lines to study mitochondrial iron accumulation. |
View FTMT Products |
| Benchmark Ab | Anti-FTMT Recombinant Antibody Recombinant positive control for Western Blot, IHC, and ELISA validation. |
View FTMT Products |
| Validator | FTMT siRNA Set For knockdown verification in ferroptosis and iron-overload cellular models. |
View FTMT Products |
| Related Target A | FTH1 (Ferritin Heavy Chain 1) Cytosolic counterpart of FTMT; critical for comparing cytosolic vs. mitochondrial iron storage. |
View FTH1 Products |
| Related Target B | FTL (Ferritin Light Chain) Co-assembles with FTH1; essential for systemic and intracellular iron homeostasis profiling. |
View FTL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mitochondrial targeting & localization validation | Lentivirus-mediated stable cell line construction for precise organelle imaging and trafficking assays. |
| Cross-reactivity & selectivity screening | High-purity homologous proteins (FTH1, FTL) available to perform counter-screening assays. |
| Lack of Controls | Sequence-verified clinical-grade recombinant antibodies included as positive assay controls. |
| False Positives in knockdown assays | Chemically-synthesized, sequence-verified siRNA pools for highly specific target validation. |
Live FTMT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FTMT therapeutics is intensifying, with major players shifting focus from traditional systemic iron chelators to targeted mitochondrial iron modulation and ferroptosis induction. As first-generation therapies reach the clinic, the next wave of R&D is targeting FTMT as a crucial node in myelodysplastic syndromes (MDS), neurodegenerative diseases (like Friedreich's ataxia), and therapy-resistant cancers where mitochondrial iron metabolism is reprogrammed.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Therapy-Resistant Cancers, Ferroptosis Induction | Enzymatic & Binding Assays (Need high-purity recombinant FTMT protein) |
| Gene Therapy / mRNA | Rare Disease Biotechs | Friedreich's Ataxia, Sideroblastic Anemia | Overexpression Validation (Need Lentivirus for stable cell lines) |
| RNA Interference (siRNA) | RNAi Specialists | Myelodysplastic Syndromes (MDS) | Knockdown Efficiency Validation (Need validated siRNA and qPCR controls) |